---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-125054"
form_type: "8-K"
ticker: "REPL"
cik: "0001737953"
company_name: "Replimune Group, Inc."
filed_at: "2022-12-07T23:59:59+00:00"
generated_at: "2026-06-21T08:13:20.157257+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Replimune reports 36% ORR in anti-PD1 failed melanoma; enters Roche collaboration for RP2/3

## Summary
- Collaboration with Roche to develop RP3 with atezolizumab/bevacizumab in 3L CRC and 1L/2L HCC; cost sharing; Phase 2 start H1 2023.
- IGNYTE anti-PD1 failed melanoma: 36% ORR, 20% CR rate in first 75 patients; 85% of responses ongoing; systemic activity seen.
- RP2/3 update: uveal melanoma 28.6% ORR (4/14 evaluable); soft tissue sarcoma 3/5 responding; responses durable.
- Phase 2 plans for RP2/3: SCCHN (130 patients), HCC (60), CRC (60); enrollment in H1 2023.

## SEC filing metadata
- accession: 0001104659-22-125054
- form_type: 8-K
- ticker: REPL
- cik: 0001737953
- company_name: Replimune Group, Inc.
- filed_at: 2022-12-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737953/000110465922125054/0001104659-22-125054-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737953/000110465922125054/tm2232156d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-125054
- JSON: https://secwatch.observer/filing/0001104659-22-125054.json
- Plain text: https://secwatch.observer/filing/0001104659-22-125054.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.